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Background: Many genetic and environmental factors are involved in the etiology of nicotine dependence.
Although several candidate gene variations have been reported by candidate gene studies or genome-wide
association studies (GWASs) to be associated with smoking behavior and the vulnerability to nicotine dependence,
such studies have been mostly conducted with subjects with European ancestry. However, genetic factors have
rarely been investigated for the Japanese population as GWASs. To elucidate genetic factors involved in nicotine
dependence in Japanese, the present study comprehensively explored genetic contributors to nicotine
dependence by using whole-genome genotyping arrays with more than 200,000 markers in Japanese subjects.
Results: The subjects for the GWAS and replication study were 148 and 374 patients, respectively. A two-stage
GWAS was conducted using the Fagerström Test for Nicotine Dependence (FTND), Tobacco Dependence Screener
(TDS), and number of cigarettes smoked per day (CPD) as indices of nicotine dependence. For the additional
association analyses, patients who underwent major abdominal surgery, patients with methamphetamine
dependence/psychosis, and healthy subjects with schizotypal personality trait data were recruited. Autopsy
specimens with various diseases were also evaluated. After the study of associations between more than 200,000
marker single-nucleotide polymorphisms (SNPs) and the FTND, TDS, and CPD, the nonsynonymous rs2653349 SNP
(located on the gene that encodes orexin [hypocretin] receptor 2) was selected as the most notable SNP associated
with FTND, with a p value of 0.0005921 in the two-stage GWAS. This possible association was replicated for the
remaining 374 samples. This SNP was also associated with postoperative pain, the initiation of methamphetamine
use, schizotypal personality traits, and susceptibility to goiter.
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Conclusions: Although the p value did not reach a conventional genome-wide level of significance in our
two-stage GWAS, we obtained significant results in the subsequent analyses that suggest that the rs2653349 SNP
(Val308Ile) could be a genetic factor that is related to nicotine dependence and possibly pain, schizotypal
personality traits, and goiter in the Japanese population.Background
Despite the worldwide spread of cigarette smoking, many
tobacco users are reportedly unaware of the harmful che-
micals in tobacco products and tobacco smoke and the
wide spectrum of specific illnesses that are caused by
tobacco use [1]. They also frequently do not know that
smoking can cause cancer (other than lung cancer), heart
disease, stroke, and many other diseases [2]. Direct to-
bacco smoking is currently responsible for the death of
approximately 5 million people worldwide each year, with
many of these deaths occurring prematurely [3, 4]. In
Japan, the proportion of deaths that are attributable to
tobacco is estimated to be 17 % for ages 30 and over [3].
Therefore, decreasing the frequency of cigarette smoking
is imperative to prevent diseases caused by tobacco use.
However, many smokers are not easily able to quit smok-
ing because of the addictive property of nicotine, a major
component of tobacco.
The heritability of nicotine dependence is estimated to
range from 0.40 to 0.75 [5–7], and many genetic and
environmental factors have been implicated in the etiology
of the disorder. To date, several candidate gene variations
have been reported to be associated with smoking behavior
and the vulnerability to nicotine dependence. These were
found mostly by investigating single-nucleotide polymor-
phisms (SNPs) on each gene related to specific phenotypes
or genome-wide association studies (GWASs), which
evaluate genetic markers in the entire genome. By taking
the former candidate gene approach, several SNPs have
been found to be associated with smoking behavior or nico-
tine dependence [8, 9]. The latter genome-wide approach
has also successfully identified numerous candidate SNPs
that may contribute to the etiology of nicotine dependence
or smoking-related behavior [10–23]. The strongest signal
of association appears to be SNPs at 15q25, represented
by a synonymous rs1051730 SNP or nonsynonymous
rs16969968 SNP in the region of CHRNA5–CHRNA3–
CHRNB4, which encodes neuronal nicotinic acetylcholine
receptor subunits [16–21]. However, these studies were
conducted with subjects with mostly European or African
ancestry [10–23]. Although a recent study that used
Korean samples found loci that influence smoking initi-
ation and nicotine dependence other than those identified
in studies with samples of European origin [24], the
applicability of the results to Japanese or other Asian pop-
ulations is unknown.To elucidate the genetic factors that are involved in nico-
tine dependence in the Japanese population, the present
study comprehensively explored genetic contributors to
nicotine dependence using whole-genome genotyping ar-
rays with more than 200,000 markers in Japanese subjects.
Results
Genome-wide association study identifies a locus
associated with nicotine dependence in a Japanese
population
In the first exploratory stage analysis of the two-stage
GWAS, 11,968, 10,865, and 11,244 SNPs showed p values
less than the threshold (p = 0.05) and were selected as
candidates for the second-stage analysis for the FTND,
TDS, and CPD. In the second stage analysis and LD-based
SNP pruning, 273, 250, and 248 SNPs showed p values
less than the threshold (p = 0.05) for the FTND, TDS, and
CPD, respectively. These SNPs were considered potent
candidates, and SNPs for the replication study were se-
lected from among these SNPs. The top 50 candidate
SNPs with the lowest p values for the FTND, TDS, and
CPD are presented in Tables 1, 2, and 3, respectively. The
top 51–100 candidate SNPs for the FTND, TDS, and
CPD are presented in Additional file 1: Table S1,
Additional file 2: Table S2, and Additional file 3: Table
S3, respectively. Several candidate SNPs after the
second-stage analysis were found to be located within
or around the gene regions that were already identified
as candidate loci associated with nicotine dependence
or smoking behavior (Additional file 4: Table S4).
Additionally, several SNPs or related genes that were
selected after the second-stage analysis commonly
appeared in the lists of candidates that resulted from
the analysis for different phenotypic measures of nico-
tine dependence (Additional file 4: Table S4).
Although the p values for the top candidate SNPs were
not sufficiently low when considering the conventional
genome-wide level of significance, the list of the top 50
candidate SNPs (Tables 1, 2, 3) was found to include a few
nonsynonymous SNPs that involve amino-acid changes
and are expected to have a greater impact on the functions
of gene products than other SNPs. Therefore, the best of
these candidates for the FTND and CPD, rs2653349 (Rank
50) and rs726016 (Rank 1), respectively, were considered
for the further confirmatory replication study (Tables 1
and 3). In the replication study, of the two SNPs, only the
Table 1 Top 50 candidate SNPs possibly associated with nicotine dependence (FTND score). CHR, chromosome number; Position, chromosomal position (bp); Related gene, the
nearest gene from the SNP site
Rank CHR SNP Position Genotypeb(FTND≥ 4) Genotypeb(FTND < 4) χ2 p Related gene Region MAF TFBS Splicing Polyphen
1 6 rs12333016 107205884 0/21/42 0/4/80 20.82 5.04E-06 QRSL1 intron 0.08503401 - - -
2 2 rs11890985 116384532 2/30/31 0/15/70 19.21 1.17E-05 DPP10 3′ flanking 0.16554054 - - -
3 13 rs7984684 43517893 0/17/43 8/45/31 19.1 1.24E-05 LOC121838 3′ flanking 0.27083333 - - -
4 5 rs1009069 167806516 2/22/39 0/9/76 16.41 5.11E-05 WWC1 intron 0.11824324 - - -
5 5 rs4958493 151090416 0/18/45 0/4/81 16.28 5.45E-05 ATOX1 3′ flanking 0.07432432 - - -
6 6 rs7754752 54272356 0/7/56 2/33/50 16.12 5.96E-05 TINAG 5′ flanking 0.14864865 - - -
7 5 rs4976553 167800531 4/33/26 28/39/18 15.56 8.01E-05 WWC1 intron 0.45945946 - - -
8 13 rs7323018 43513039 3/25/35 16/47/22 15.46 8.42E-05 LOC121838 3′ flanking 0.37162162 - - -
9 13 rs4631996 98096579 0/3/60 1/25/59 15.06 1.04E-04 LOC643193 5′ flanking 0.10135135 - - -
10 2 rs10176321 235561801 7/30/26 27/44/14 15 1.08E-04 SH3BP4 intron 0.47972973 - - -
11 13 rs1768047 98126380 0/6/57 2/30/53 14.99 1.08E-04 SLC15A1 3′ flanking 0.13513514 - - -
12 4 rs2390944 127169897 0/4/59 1/27/57 14.94 1.11E-04 LOC645841 5′ flanking 0.11148649 - - -
13 13 rs9533755 43530210 1/20/42 11/42/32 14.54 1.37E-04 LOC121838 3′ flanking 0.29054054 - - -
14 2 rs2042831 235521853 5/36/22 26/46/13 14.53 1.38E-04 SH3BP4 5′ flanking 0.48648649 + - -
15 2 rs1542604 131309515 3/22/38 1/9/75 14.47 1.42E-04 LOC730032 5′ flanking 0.13175676 + - -
16 1 rs188158 26770729 9/33/21 4/26/55 14.44 1.45E-04 RPS6KA1 intron 0.28716216 - - -
17 13 rs696938 92529022 8/26/29 3/17/65 14.37 1.50E-04 GPC6 5′ flanking 0.21959459 - - -
18 10 rs7924276 132704843 26/27/10 12/44/29 14.33 1.53E-04 TCERG1L 3′ flanking 0.49662162 - - -
19 12 rs6488995 124375941 13/32/18 5/32/48 14.24 1.61E-04 TMEM132B 5′ flanking 0.33783784 + - -
20 13 rs4772116 98100046 0/0/63 0/17/68 14.24 1.61E-04 LOC643193 5′ flanking 0.05743243 - - -
21 1 rs3895368 228949696 1/13/49 4/42/39 14.13 1.70E-04 CAPN9 5′ flanking 0.21959459 + - -
22 5 rs2973808 177699186 8/25/30 2/19/64 13.74 2.10E-04 COL23A1 intron 0.21621622 - - -
23 2 rs4668703 11052055 22/31/10 13/37/35 13.63 2.23E-04 KCNF1 3′ flanking 0.46621622 - - -
24 15 rs12591960 87909455 3/19/41 11/45/28 13.62 2.24E-04 C15orf42 5′ flanking 0.31292517 - - -
25 5 rs9314227 97581046 6/31/26 27/41/17 13.46 2.44E-04 LOC642909 5′ flanking 0.46621622 - - -
26 8 rs3862072 65564638 7/28/28 26/42/17 13.41 2.50E-04 BHLHB5 5′ flanking 0.45945946 - - -
27 15 rs4887435 84682665 7/26/30 0/24/61 13.23 2.76E-04 LOC727915 5′ flanking 0.21621622 - - -
28 8 rs7819541 22098096 0/4/59 4/22/59 13.12 2.92E-04 BMP1 intron 0.11486486 - - -
29 6 rs2021678 102140234 0/5/58 3/25/57 13.12 2.93E-04 GRIK2 intron 0.12162162 - - -
30 18 rs9303903 2433818 16/38/9 12/35/38 12.83 3.41E-04 METTL4 3′ flanking 0.43581081 - - -
31 6 rs16882180 52164345 11/35/17 6/31/48 12.83 3.42E-04 IL17A 3′ flanking 0.33783784 - - -













Table 1 Top 50 candidate SNPs possibly associated with nicotine dependence (FTND score). CHR, chromosome number; Position, chromosomal position (bp); Related gene, the
nearest gene from the SNP site (Continued)
33 6 rs17082273 152529619 0/2/61 0/21/64 12.78 3.50E-04 SYNE1 intron 0.0777027 - + -
34 16 rs11862729 14053599 6/38/19 3/31/51 12.77 3.53E-04 MKL2 5′ flanking 0.29391892 - - -
35 3 rs6807108 146970672 6/30/27 3/20/62 12.73 3.60E-04 LOC389156 3′ flanking 0.22972973 - - -
36 10 rs1909669 123376244 18/34/11 9/42/34 12.6 3.87E-04 LOC729426 intron 0.43918919 - - -
37 13 rs1927382 101940250 1/17/45 0/6/79 12.55 3.97E-04 FGF14 5′ flanking 0.08445946 - - -
38 2 rs17028222 60529867 1/10/52 3/37/45 12.52 4.03E-04 BCL11A 3′ flanking 0.18581081 - - -
39 6 rs2237204 16532935 14/31/18 6/33/46 12.51 4.04E-04 ATXN1 intron 0.35135135 - - -
40 21 rs2242936 39345341 0/8/55 1/32/52 12.44 4.20E-04 LOC391282 5′ flanking 0.14189189 - - -
41 7 rs715205 122188782 0/14/49 0/3/82 12.44 4.21E-04 CADPS2 intron 0.05743243 - - -
42 16 rs289741 55574975 7/27/29 19/51/15 12.4 4.29E-04 CETP intron 0.43918919 - - -
43 10 rs12416632 37323355 8/24/31 21/47/17 12.2 4.78E-04 LOC646348 5′ flanking 0.43581081 + - -
44 1 rs7512726 204899584 9/34/20 3/33/49 12.19 4.81E-04 DYRK3 3′ flanking 0.30743243 - - -
45 14 rs11627505 85145744 0/15/48 9/32/44 12.06 5.16E-04 FLRT2 5′ flanking 0.21959459 - - -
46 1 rs1891243 222754068 2/28/33 1/16/68 12.01 5.29E-04 WDR26 5′ flanking 0.16891892 - - -
47 17 rs2309381 5209436 24/29/10 11/48/26 11.99 5.35E-04 RABEP1 intron 0.49662162 - - -
48 2 rs10166654 236276002 9/25/29 26/42/17 11.97 5.41E-04 CENTG2 intron 0.46283784 - - -
49 7 rs10230426 18699683 2/27/34 1/15/69 11.89 5.66E-04 HDAC9 intron 0.16216216 - - -
50 6 rs2653349 55250296 0/15/48 0/4/81 11.8 5.92E-04 HCRTR2 non-syna 0.06418919 - + benign
a, coding region (nonsynonymous polymorphism);
b, distribution of genotype (homozygote of minor allele/heterozygote/homozygote of major allele);
MAF, minor allele frequency; TFBS, SNPs located at a transcription factor-binding site (TFBS) of a gene;
Splicing, SNPs located at exonic splicing enhancer (ESE) or exonic splicing silencer (ESS);













Table 2 Top 50 candidate SNPs possibly associated with nicotine dependence (TDS score)
Rank CHR SNP Position Genotypeb(TDS≥ 3) Genotypeb(TDS < 3) χ2 p Related gene Region MAF TFBS Splicing Polyphen
1 18 rs11662608 60876992 7/38/33 22/36/11 18.28 1.90E-05 CDH7 5′ flanking 0.44897959 - - -
2 2 rs10490099 58991504 6/40/33 0/19/50 16.33 5.33E-05 LOC730134 3′ flanking 0.23986486 - - -
3 13 rs17056451 37163539 8/44/24 2/22/45 16.24 5.59E-05 TRPC4 intron 0.29655172 - - -
4 4 rs13112895 60509294 18/40/21 5/24/40 16.17 5.80E-05 LOC644419 5′ flanking 0.37162162 - - -
5 9 rs10973120 36885382 5/20/54 9/38/22 15.88 6.76E-05 PAX5 intron 0.29054054 - - -
6 18 rs611411 60899889 26/43/10 10/31/28 15.82 6.95E-05 CDH7 5′ flanking 0.49324324 - - -
7 18 rs176136 60936692 18/43/18 5/28/36 15.61 7.80E-05 CDH7 5′ flanking 0.39527027 - - -
8 18 rs176121 60958616 14/42/23 4/23/42 15.28 9.28E-05 CDH7 5′ flanking 0.34121622 - - -
9 2 rs985162 129883821 10/44/25 0/29/40 15.18 9.76E-05 LOC402102 5′ flanking 0.31418919 - - -
10 5 rs1366589 84922599 11/35/33 4/12/53 15.17 9.81E-05 LOC645181 3′ flanking 0.26013514 - - -
11 18 rs12962611 18303667 5/47/27 0/25/44 15.1 1.02E-04 CTAGE1 5′ flanking 0.27702703 - - -
12 1 rs909530 169349798 16/46/17 4/31/34 15.06 1.04E-04 FMO3 syna 0.39527027 - + -
13 1 rs12032382 207272695 0/10/69 0/28/41 15.05 1.05E-04 LOC391157 5′ flanking 0.12837838 - - -
14 13 rs9532107 37187961 2/24/53 13/28/28 15.01 1.07E-04 TRPC4 intron 0.27702703 - - -
15 5 rs7719216 8023898 3/20/56 7/36/26 14.97 1.09E-04 MTRR 3′ flanking 0.25675676 - - -
16 4 rs923665 38214103 0/5/72 1/20/46 14.96 1.10E-04 NULL 3′ flanking 0.09375 - - -
17 15 rs28716882 21552860 3/28/48 0/8/61 14.94 1.11E-04 NDN 5′ flanking 0.14189189 - - -
18 2 rs875063 111529556 10/32/37 20/37/12 14.92 1.12E-04 ACOXL intron 0.43581081 - - -
19 4 rs13144500 183475934 1/9/69 3/26/40 14.91 1.13E-04 ODZ3 intron 0.14527027 - - -
20 6 rs1772253 24528213 4/35/40 0/14/55 14.76 1.22E-04 MRS2L intron 0.19256757 - - -
21 4 rs2866688 78968066 4/38/37 2/11/55 14.74 1.24E-04 CNOT6L 5′ flanking 0.20748299 - - -
22 12 rs17120420 56856068 18/44/16 4/34/31 14.45 1.44E-04 LOC338805 5′ flanking 0.41496599 - - -
23 17 rs16946572 12604902 7/30/42 17/35/17 14.32 1.54E-04 MYOCD intron 0.38175676 - - -
24 18 rs4328535 70129056 12/39/28 0/28/41 14.16 1.68E-04 DKFZP781G0119 5′ flanking 0.30743243 + - -
25 16 rs10514585 81841839 7/43/29 22/35/12 14.16 1.68E-04 CDH13 intron 0.45945946 - - -
26 16 rs1379652 17304099 13/39/25 2/26/41 14.09 1.74E-04 XYLT1 intron 0.32534247 - - -
27 6 rs2496167 13450101 9/33/37 17/40/12 13.91 1.92E-04 TBC1D7 5′ flanking 0.4222973 - - -
28 11 rs623312 31864040 19/43/17 5/32/32 13.76 2.08E-04 LOC729605 5′ flanking 0.41554054 - - -
29 2 rs1403858 36566018 0/23/55 0/4/65 13.7 2.14E-04 CRIM1 intron 0.09183673 - - -
30 6 rs1591996 8291461 0/3/76 0/17/52 13.69 2.16E-04 SLC35B3 3′ flanking 0.06756757 - - -
31 9 rs4877369 89514689 8/26/45 19/30/20 13.65 2.20E-04 DAPK1 3′ flanking 0.37162162 - - -
32 16 rs17765854 64608419 21/43/15 7/31/31 13.63 2.22E-04 CDH5 5′ flanking 0.43918919 - - -













Table 2 Top 50 candidate SNPs possibly associated with nicotine dependence (TDS score) (Continued)
34 16 rs2305689 69354016 10/30/39 19/36/14 13.48 2.41E-04 VAC14 intron 0.41891892 - - -
35 8 rs2975701 10147867 0/8/71 1/23/45 13.44 2.47E-04 MSRA intron 0.11148649 - - -
36 2 rs1567852 174440084 1/22/56 0/4/65 13.33 2.61E-04 LOC344178 3′ flanking 0.09459459 - - -
37 7 rs1540893 143398486 18/31/29 2/26/41 13.27 2.70E-04 OR2A25 5′ flanking 0.32993197 + - -
38 1 rs6686733 4663049 4/28/47 0/10/59 13.26 2.71E-04 AJAP1 intron 0.15540541 - - -
39 13 rs9555699 109898019 3/28/48 12/33/24 13.12 2.92E-04 COL4A2 intron 0.30743243 - - -
40 15 rs10851750 63908644 6/26/47 17/29/23 13.03 3.06E-04 DENND4A 5′ flanking 0.34121622 - - -
41 10 rs520887 78720167 3/29/47 0/10/59 12.98 3.15E-04 KCNMA1 intron 0.15202703 - - -
42 6 rs573668 13446548 1/30/48 11/32/26 12.94 3.21E-04 TBC1D7 5′ flanking 0.29054054 - - -
43 20 rs4810359 40624749 10/30/39 1/16/52 12.84 3.39E-04 PTPRT intron 0.22972973 - - -
44 12 rs10771391 27966867 23/41/15 6/36/27 12.84 3.40E-04 PTHLH 3′ flanking 0.45608108 - - -
45 14 rs2415449 37667678 13/41/25 2/28/39 12.83 3.42E-04 LOC729122 intron 0.33445946 - - -
46 7 rs3807171 37875304 11/39/29 2/23/44 12.82 3.43E-04 TXNDC3 intron 0.2972973 - - -
47 4 rs7667301 53395322 3/31/45 12/35/22 12.79 3.48E-04 RASL11B 5′ flanking 0.32432432 - - -
48 17 rs2188889 13178372 3/27/49 10/35/24 12.72 3.62E-04 HS3ST3A1 3′ flanking 0.2972973 - - -
49 5 rs6875661 54360379 9/37/33 16/43/10 12.65 3.76E-04 GZMK intron 0.43918919 - - -
50 7 rs2058024 25742215 15/39/25 3/27/39 12.57 3.92E-04 LOC646588 5′ flanking 0.34459459 - - -
CHR, chromosome number; Position, chromosomal position (bp); Related gene, the nearest gene from the SNP site;
a, coding region (synonymous polymorphism);
b, distribution of genotype (homozygote of minor allele/heterozygote/homozygote of major allele);
MAF, minor allele frequency; TFBS, SNPs located at a transcription factor-binding site (TFBS) of a gene;
Splicing, SNPs located at exonic splicing enhancer (ESE) or exonic splicing silencer (ESS);













Table 3 Top 50 candidate SNPs possibly associated with nicotine dependence (CPD)
Rank CHR SNP Position Genotypeb(CPD > 20) Genotypeb(CPD≤ 20) χ2 p Related gene Region MAF TFBS Splicing Polyphen
1 2 rs726016 234390241 0/21/15 0/20/92 22.29 2.35E-06 LOC339766 non-syna 0.13851351 - + probablydamaging
2 2 rs960615 151441447 4/20/12 3/25/84 20.45 6.11E-06 LOC727840 3′ flanking 0.19932432 - - -
3 2 rs11683427 127673013 1/10/25 0/5/107 19.71 9.00E-06 CYP27C1 intron 0.05743243 - - -
4 17 rs4077548 75345351 8/25/3 10/44/57 19.14 1.21E-05 ENPP7 3′ flanking 0.35714286 - - -
5 7 rs2888674 150141848 3/22/11 1/34/77 18.94 1.35E-05 TMEM176A 3′ flanking 0.21621622 - - -
6 7 rs4721629 17542242 1/17/18 0/18/94 18.26 1.93E-05 AHR 3′ flanking 0.125 - - -
7 15 rs10518761 54535156 0/9/27 0/3/109 18.22 1.97E-05 UNC13C intron 0.04054054 - - -
8 18 rs8093458 65163508 7/20/9 2/47/62 17.45 2.94E-05 DOK6 5′ flanking 0.28911565 - - -
9 21 rs8127336 27297806 3/12/21 0/15/97 17.08 3.59E-05 ADAMTS5 5′ flanking 0.11148649 - - -
10 10 rs10904919 17374751 0/18/18 0/18/94 17.04 3.67E-05 ST8SIA6 3′ flanking 0.12162162 - - -
11 7 rs12540772 150160296 6/20/10 3/40/69 16.8 4.16E-05 ABP1 5′ flanking 0.26351351 - - -
12 2 rs1542604 131309515 3/14/19 1/17/94 16.35 5.26E-05 LOC730032 5′ flanking 0.13175676 + - -
13 1 rs10494797 197762985 6/16/14 2/33/77 15.39 8.75E-05 LOC647202 3′ flanking 0.21959459 - - -
14 1 rs6683501 197753037 6/15/15 0/36/76 15.37 8.84E-05 LOC647202 3′ flanking 0.21283784 - - -
15 20 rs4811238 36491682 0/0/36 1/36/75 15.35 8.95E-05 CTNNBL1 intron 0.12837838 - - -
16 7 rs11772167 150134012 2/13/21 0/16/96 14.76 1.22E-04 TMEM176A 3′ flanking 0.11148649 + - -
17 21 rs8126747 41902438 7/18/11 5/37/70 14.59 1.33E-04 TMPRSS2 5′ flanking 0.26689189 - - -
18 15 rs1434462 77306926 0/8/28 11/54/47 14.4 1.48E-04 LOC646956 5′ flanking 0.28378378 - - -
19 7 rs9792016 13823760 7/19/10 7/35/70 14.34 1.53E-04 LOC646161 5′ flanking 0.27702703 - - -
20 21 rs2830596 27276913 7/19/10 5/41/66 14.22 1.62E-04 ADAMTS5 5′ flanking 0.28378378 - - -
21 2 rs11902906 143299978 3/13/20 26/63/23 14.21 1.64E-04 KYNU 5′ flanking 0.4527027 - - -
22 1 rs6658450 197694872 6/17/13 2/38/72 14.12 1.72E-04 LOC647202 3′ flanking 0.23986486 - - -
23 1 rs1416127 56265694 1/20/15 0/29/83 14.12 1.72E-04 LOC127406 3′ flanking 0.1722973 - - -
24 14 rs799045 81687929 5/9/22 33/54/25 14.11 1.72E-04 LOC730103 5′ flanking 0.46959459 - - -
25 7 rs3814991 18601428 10/21/5 12/48/52 14.03 1.80E-04 HDAC9 intron 0.38175676 - - -
26 4 rs7659741 130342701 10/18/8 6/54/52 13.93 1.90E-04 LOC391697 5′ flanking 0.35135135 - - -
27 10 rs1570937 18798899 0/11/24 0/8/103 13.79 2.04E-04 CACNB2 intron 0.06506849 - - -
28 4 rs13435610 181024788 2/17/17 0/26/86 13.79 2.05E-04 LOC643179 3′ flanking 0.15878378 - - -
29 12 rs11613339 39239162 1/16/19 0/20/92 13.77 2.06E-04 NULL intron 0.12837838 - - -
30 6 rs4305747 132959305 0/17/19 21/63/28 13.76 2.08E-04 TAAR5 5′ flanking 0.41216216 + - -
31 8 rs7006843 117669783 0/7/29 10/51/51 13.69 2.16E-04 EIF3H 3′ flanking 0.26351351 - - -
32 11 rs3107636 122287366 4/18/14 4/26/82 13.68 2.17E-04 C11orf63 intron 0.2027027 - - -













Table 3 Top 50 candidate SNPs possibly associated with nicotine dependence (CPD) (Continued)
34 2 rs2698537 64363458 1/12/23 0/12/100 13.66 2.19E-04 LOC130773 3′ flanking 0.08783784 - - -
35 19 rs4926219 14441328 2/11/23 0/13/99 13.64 2.21E-04 PKN1 non-syna 0.09459459 - + benign
36 3 rs1157438 22343099 9/14/13 3/43/66 13.54 2.33E-04 LOC728516 3′ flanking 0.27364865 - - -
37 7 rs6980179 150156343 9/20/7 8/50/54 13.5 2.38E-04 TMEM176A 3′ flanking 0.35135135 - - -
38 1 rs10518473 74924774 1/9/26 0/7/105 13.37 2.55E-04 C1orf173 5′ flanking 0.06081081 - - -
39 4 rs4616770 130292102 11/13/12 4/49/59 13.35 2.58E-04 LOC391697 5′ flanking 0.31081081 - - -
40 3 rs2337708 18169752 0/11/25 0/8/104 13.35 2.59E-04 SATB1 3′ flanking 0.06418919 - - -
41 1 rs17461925 201293214 5/14/17 1/29/82 13.16 2.86E-04 PPFIA4 intron 0.18581081 - - -
42 2 rs4851890 98164176 6/18/12 3/40/69 13.1 2.95E-04 VWA3B intron 0.25675676 - - -
43 2 rs6759709 2026404 0/2/34 5/38/69 13.01 3.09E-04 MYT1L intron 0.16891892 - - -
44 18 rs1567041 4485320 16/12/8 14/52/46 12.99 3.14E-04 LOC388458 5′ flanking 0.41891892 - - -
45 3 rs149863 138965053 4/12/20 0/23/89 12.84 3.39E-04 SOX14 5′ flanking 0.14527027 + - -
46 11 rs7945313 91134747 12/12/12 5/50/57 12.83 3.41E-04 LOC727998 3′ flanking 0.32432432 - - -
47 19 rs10417021 62642189 0/12/24 0/10/102 12.82 3.43E-04 ZNF749 5′ flanking 0.07432432 - - -
48 25 rs5988531 884198 2/21/13 2/32/78 12.79 3.48E-04 SHOX | CRLF2 intergenic 0.20608108 not available not available not available
49 4 rs17051378 122785148 8/17/11 4/46/62 12.72 3.62E-04 ANXA5 3′ flanking 0.29391892 - - -
50 11 rs4756986 19056814 7/15/14 4/34/74 12.68 3.69E-04 MRGPRX2 5′ flanking 0.23986486 - - -
CHR, chromosome number; Position, chromosomal position (bp); Related gene, the nearest gene from the SNP site;
a, coding region (nonsynonymous polymorphism);
b, distribution of genotype (homozygote of minor allele/heterozygote/homozygote of major allele);
MAF, minor allele frequency; TFBS, SNPs located at a transcription factor-binding site (TFBS) of a gene;
Splicing, SNPs located at exonic splicing enhancer (ESE) or exonic splicing silencer (ESS);
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FTND score (χ2 = 5.094, q = 0.048; Table 4). This SNP was
within the region of the HCRTR2 gene, which encodes
orexin (hypocretin) receptor 2.
Imputation analysis was further conducted for SNPs
around the rs2653349 SNP for the GWAS samples. As a
result, several SNPs whose genotypes were imputed ex-
hibited strong associations similarly to the rs2653349
SNP. These SNPs (rs2653342, rs2653343, rs2653344,
and rs2653347) were located at a slightly upstream re-
gion of the rs2653349 SNP (Fig. 1). However, our data-
base search with SNPinfo Web Server (see Additional
file 5: Supporting Information) revealed that all of these
SNPs were in absolute linkage disequilibrium with the
rs2653349 SNP (D′ = r2 = 1). Given that genotype call
ratios by whole-genome genotyping or imputation for
the rs2653342, rs2653343, rs2653344, rs2653347, and
rs2653349 SNPs were 99.0 %, 97.7 %, 100.0 %, 98.0 %,
100.0 %, and 100.0 %, respectively, the apparently stron-
ger associations that were observed for the rs2653342,
rs2653343, and rs2653347 SNPs than for the rs2653349
SNP were merely attributable to the incomplete geno-
type data for these SNPs. Therefore, the contribution of
the rs2653342, rs2653343, rs2653344, and rs2653347
SNPs to nicotine dependence was regarded as statisti-
cally equal to that of the rs2653349 SNP. Considering
that rs2653349 is a nonsynonymous SNP and the others
are located in the intronic region of the HCRTR2 gene,
one could assume that this SNP is most likely the causa-
tive SNP.
Association between rs2653349 SNP and postoperative
pain in patients who underwent major open abdominal
surgery
To examine whether the rs2653349 SNP that was identi-
fied in our GWAS affects individual differences in the
sensitivity to some drugs and pain, we investigated the
association between the rs2653349 SNP and postoperative
opioid requirements and pain in another cohort who
underwent major open abdominal surgery (Additional file
6: Table S5). The subjects included 112 patients who
underwent major open abdominal surgery under com-
bined general and epidural anesthesia (Additional file 6:
Table S5). Significant associations were not found for the
frequency of analgesic administration (U = 495, p = 0.1373;
Additional file 6: Table S5) or the total dose administered
(U = 480, p = 0.1091; Additional file 6: Table S5). However,
a significant difference in pain intensity at rest during the
first 24-h postoperative period, reflected by scores on a
numerical rating scale (NRS; i.e., a 5-point verbal rating
scale, in which 0 = no pain, 1 =mild pain, 2 =moderate
pain, 3 = severe pain, and 4 = extremely severe pain), was
found between subjects with the A/G genotype and sub-
jects with the G/G genotype in the rs2653349 SNP.Furthermore, carriers of the G/G genotype complained
more about pain than carriers of the A/G genotype (U =
212, p = 0.0017; Additional file 6: Table S5), suggesting
that G/G carriers are more sensitive to postoperative pain
than A/G carriers.
Association between rs2653349 SNP and the initiation of
drug use in patients with METH dependence
We also investigated the association between the rs2653349
SNP and two measures of the severity of METH depend-
ence: age at first use of the drug (years) and number of
drugs used, including METH. Significant associations were
not found for the number of drugs used (U = 1894, p =
0.2601; Additional file 7: Table S6). However, a significant
difference was found in the first use of METH between the
subjects with the A/G genotype and subjects with the G/G
genotype in the rs2653349 SNP. Carriers of the A/G
genotype first used METH at a significantly younger age
than carriers of the G/G genotype (U = 1097, p = 0.0056;
Additional file 7: Table S6), suggesting that A/G carriers
might harbor a high risk of initiating METH use and
becoming regular users at younger ages than G/G carriers.
Association between rs2653349 SNP and schizotypal
personality trait in healthy subjects
To further examine the impact of the rs2653349 SNP on
individual differences in the vulnerability to develop other
psychiatric diseases in healthy subjects, we examined the
possible effect of the rs2653349 genotype in the HCRTR2
gene on total Schizotypal Personality Questionnaire (SPQ)
scores [25–27] using a one-way analysis of covariance
(ANCOVA). To control confounding factors, age, sex, and
years of education were used as covariates [28]. This
analysis indicated a significant effect of genotype (F1,306 =
5.80, p = 0.017; Additional file 8: Table S7). We then inves-
tigated the effect of genotype on the three SPQ factors:
cognitive/perceptual, interpersonal, and disorganization
[29]. Significant effects of genotype were found on the
cognitive/perceptual factor (F1,306 = 4.37, p = 0.037) and
disorganization factor (F1,306 = 4.19, p = 0.042; Additional
file 9: Table S8), but no effect of genotype was found on
the interpersonal factor (p > 0.09). Subjects with the risk
A/G genotype of the rs2653349 SNP had higher schizo-
typal trait scores than subjects with the G/G genotype
(Additional file 9: Table S8).
Association between rs2653349 SNP and goiter in
samples of autopsy specimens
We also investigated whether the rs2653349 SNP affects
the susceptibility to diseases other than psychiatric dis-
eases in another cohort by evaluating the association be-
tween this SNP and a total of 104 diseases/phenotypes
using autopsy specimens (Additional file 10: Table S9).
Nominally significant associations were found between
Table 4 Results of confirmatory association analysis between the selected SNPs and nicotine dependence





geneχ2 p χ2 p q χ2 p
rs2653349 6 55250296 FTND 12.3 0.0005921 5.094 0.024 0.048* 14.02 0.0001806 0/41/203 0/17/252 HCRTR2
rs726016 2 234390241 CPD 22.29 0.00000235 0.471 0.4925 0.4925 3.023 0.08209 2/41/94 4/87/293 LOC339766













Fig. 1 Fine mapping of the candidate region after the imputation-based association analysis. The circle plot represents the results of the association
analysis in a trend model using the GWAS samples. The range for the X-axis represents the genomic position from 55,100,000 to 55,400,000
on chromosome 6 in the HapMap database (http://hapmap.ncbi.nlm.nih.gov/index.html.ja; accessed July 15, 2015). The green object above
the plot illustrates the schematic structure of the human HCRTR gene (Gene Accession no. NM_001526.3), based on the NCBI database (http://
www.ncbi.nlm.nih.gov/gene/; accessed July 15, 2015). The gene is illustrated between the 5’- and 3’-flanking regions, corresponding to left
and right sides, respectively. The green vertical lines and horizontal line that connects them represent the exon and intron, respectively
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sclerosis and the rs2653349 SNP. Carriers of the A/G
genotype were more frequently in the disease group than
in the control group (Additional file 11: Table S10). The
association between this SNP and goiter was much stron-
ger than the associations with the other three diseases
(Additional file 11: Table S10). These results suggest that
A/G carriers may harbor a higher risk of developing these
diseases than G/G carriers.
Discussion
Previous GWASs on nicotine dependence that used sam-
ples of mainly European origin identified numerous candi-
date SNPs [10–23]. Several of the candidate SNPs in the
present study after the second-stage analysis were found
to be located within or around the gene regions that have
already been identified as candidate loci associated with
nicotine dependence or smoking behavior (Additional file
4: Table S4). These candidate genetic factors may be com-
mon to some populations other than Japanese. Addition-
ally, several SNPs or related genes that were selected after
the second-stage analysis commonly appeared in the lists
of candidates that resulted from the analysis of different
phenotypic measures of nicotine dependence (Additional
file 4: Table S4). These SNPs/genes might be candidates
that possibly contribute to several aspects of dependence
simultaneously. Among these candidate SNPs/genes were
CSMD1 and IMMP2L, which were selected as candidate
genes to test associations with the FTND, TDS, and CPD(Additional file 4: Table S4). CSMD1, a tumor suppressor
gene [30], is a known candidate for nicotine dependence
[11]. The SNPs in the region of CHRNA5–CHRNA3–
CHRNB4 at 15q25, which have been reported to show
strong associations with CPD in studies with subjects with
European ancestry [16–18], were not included in our list of
the top 100 candidates (Tables 1, 2, 3, Additional file 1:
Table S1, Additional file 2: Table S2, Additional file 3: Table
S3). Although definitive conclusions cannot be drawn until
further studies are conducted with larger sample sizes, the
SNPs in this region might not greatly affect the severity of
nicotine dependence in the Japanese population.
The best candidate SNP, rs2653349, is located within
the HCRTR2 gene on chromosome 6 (Table 4). The
HCRTR2 gene encodes orexin receptor 2. The orexin
receptor has two subtypes (orexin receptor 1 [HCRTR1]
and orexin receptor 2 [HCRTR2]) and two known neuro-
peptide ligands (orexin A, which binds both HCRTR1 and
HCRTR2, and orexin B, which binds only HCRTR2).
Orexin peptides, whose mRNA initially identified them as
a hypothalamus-specific peptides with neuroexcitatory
activity [31], and their receptors are distributed in various
tissues, including the hypothalamus and pituitary [32–34].
They are well known to regulate feeding behavior and
states of sleep/wakefulness [32, 35]. Orexin knockout mice
were reported to exhibit an attenuation of morphine
dependence [36]. The hypocretin receptor 1 antagonist
SB334867 and hypocretin receptor 1/2 antagonist almor-
exant both dose-dependently reduced nicotine self-
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orexin system in the rewarding effects.
Our further study that examined whether the rs2653349
SNP affects individual differences in the susceptibility to
other diseases or phenotypic traits suggested that A/G
genotype carriers of this SNP are less sensitive to postoper-
ative pain (Additional file 6: Table S5), have a high risk of
initiating METH use regularly at younger ages (Additional
file 7: Table S6), have higher schizotypal trait scores
(Additional file 9: Table S8), and harbor a higher risk of de-
veloping goiter, aortic aneurysm, and myeloma than G/G
carriers (Additional file 11: Table S10). For this SNP [38],
several previous reports demonstrated an association with
cluster headache [39–41]. Intriguingly, carriers of the G/G
genotype have been reported to have a higher disease risk
than the other genotypes. Given the modulation of antino-
ciceptive effects by the orexin system in various animal
models of pain [42], one speculation is that G/G carriers
are generally more sensitive to pain because of dampened
activity of the orexin system. The severer levels of nicotine
dependence in A/G genotype carriers of this SNP may be
attributable to increased rewarding effects related to the
orexin system, possibly leading to a higher risk of initiating
METH use regularly at younger ages. The higher schizo-
typal trait scores in A/G carriers than in G/G carriers in
the present study may be explained by orexin-induced
activation of the mesolimbic dopamine system, which may
underlie some of its actions in schizophrenia [43]. Previous
reports indicated that nicotine dependence was more
frequent in smokers with schizophrenia compared with the
general population [44]. Chronic schizophrenia patients
also have lower visual analogue scale postoperative pain
scores than control patients [45], which appears to be
consistent with the trend observed in the present study.
Less understood is the involvement of the orexin system in
goiter, aortic aneurysm, myeloma, and amyotrophic lateral
sclerosis. However, the increased frequency of cigarette
smoking associated with severer levels of nicotine depend-
ence in A/G carriers of this SNP may cause an elevation of
thiocyanate synthesis [46], which would then enhance the
risk of goiter [47–49].
Our database search estimated that the possible impact
of the amino-acid substitution from valine to isoleucine by
the base substitution from G to A in the rs2653349 SNP on
the structure and function of human protein is predicted to
be “benign.” Indeed, few studies have investigated the
functional alterations caused by the rs2653349 SNP. A pre-
vious report only showed that the SNP, located in the exon
5 region, had no effect on orexin binding sites, but the
corresponding residue Val308Ile might be at the dimer
interface and influence the dimerization process of the
receptor [50]. Further functional studies will be needed to
provide a clearer explanation for the associations observed
in human studies between the SNP and phenotypic traits.With regard to our initial GWAS that was conducted as
a consecutive two-stage analysis, the lowest exploratory p
value for the entire sample was > ~1 × 10−6 (Tables 1, 2, 3),
which would have been deemed genome-wide nonsignifi-
cant if only a single-stage analysis was performed to calcu-
late conventional Bonferroni- or FDR-corrected p values
for the total samples to determine statistical significance.
The situation would not have been improved even if only
non-synonymous SNPs had been considered in the ana-
lysis as in previous studies [51, 52] because a total of 1,413
non-synonymous SNPs were included among the 225,591
SNPs that were used in our two-stage GWAS, and the
conventionally corrected p value of the rs2653349 SNP
would have exceeded 0.05. However, “significant” results
that are obtained as conventionally corrected p values
may not always represent true associations, meaning that
the results may not be necessarily replicated in other stud-
ies, and vice versa. For example, data from the National
Human Genome Research Institute GWAS catalog (as of
January 31, 2009) showed 1,321 entries of discovered asso-
ciations with p values < 10−5, but only 550 of these entries
had p values < 5 × 10−8 [53], which is known as a conven-
tionally corrected conservative threshold for declaring a
significant association in a GWAS [54, 55]. In both cases,
truly potent candidate SNPs may be included in the out-
come of the studies. Furthermore, inconsistencies between
genome-wide significance and truly meaningful “signifi-
cance” have been exemplified by numerous studies. For
example, Bierut et al. [19] identified SNPs in the β3 nico-
tinic cholinergic receptor gene as candidates that contrib-
ute to the development of nicotine dependence based on
p values that were genome-wide nonsignificant. Thor-
geirsson et al. [18] subsequently performed a genome-
wide association meta-analysis using independent samples
and found that SNPs in this gene region were genome-
wide significantly associated with CPD (p < 5 × 10−8).
Altogether, these reports suggest that conventionally cor-
rected p values for combined samples may not be the sole
criteria for identifying true associations between SNPs and
specific phenotypes. Nevertheless, we did not obtain re-
sults with markedly low p values in the present GWAS.
Future studies are required to draw more definitive con-
clusions about associations between the rs2653349 SNP
and nicotine dependence and the other traits that were
examined in the present study.
Conclusions
Although the p value did not reach a conventional
genome-wide level of significance in our two-stage
GWAS, we obtained results in the subsequent analyses
that suggest that carriers of the A/G genotype of the non-
synonymous rs2653349 SNP are more likely to exhibit
more severe levels of nicotine dependence than carriers of
the G/G genotype in the Japanese population. This result
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ciated with the exacerbation of nicotine dependence and
may serve as a marker that predicts the severity of nico-
tine dependence in the Japanese population.
Methods
Subjects
The participants in the present study were a total of 999
patients who were ambulatory, able to communicate or-
ally, and 60 years of age or older. Of these 999 patients,
148 were included in the two-stage GWAS to explore the
association between polymorphisms in the entire human
genome and the severity of nicotine dependence. Numer-
ous participants in this study had various smoking habits
and completed a questionnaire that contained questions
about lifestyle, including alcohol consumption, smoking,
diet, and cancer history [56, 57]. The detailed demo-
graphic and clinical characteristics of the subjects are
provided in Additional file 12: Table S11.
The subsequent study that investigated the associations
between the candidate SNPs and sensitivity to pain and
analgesia included 112 patient subjects who underwent
major open abdominal surgery (age, 28–80 years; 60 males
and 52 females), mostly gastrectomy for gastric cancer
and colectomy for colorectal cancer [58, 59]. Additionally,
203 patients with methamphetamine (METH) dependence
(age, 18–69 years; 165 males and 38 females) who were
recruited for a collaborative study of the Japanese Genetics
Initiative for Drug Abuse (JGIDA) [60, 61] were also en-
rolled in the present study. Healthy subjects (age, 18–66
years; 129 males and 182 females) were also recruited for
the association study between candidate SNPs and schizo-
typal personality traits. To investigate the impact of the
candidate SNPs on the susceptibility to various diseases,
samples of 2,305 consecutive Japanese autopsy cases
(1,266 male and 1,039 female; mean age at death, 80.6 ±
8.8 years) who were registered in the Internet database of
Japanese SNPs for geriatric research [62] were also used.
The demographic and clinical data of all of these subjects
are described in the Supporting Information (Additional
file 6: Table S5, Additional file 7: Table S6, Additional file
8: Table S7, Additional file 10: Table S9) and previous
reports [58–65].
Smoking behavior data
The results of the questionnaire, especially questions
related to smoking, were used in the analysis of the sever-
ity of nicotine dependence. Some of them included the
Fagerstrӧm Test for Nicotine Dependence (FTND; a test
that yields a continuous measure of nicotine dependence)
[66] and Tobacco Dependence Screener (TDS; a screening
questionnaire for tobacco/nicotine dependence according
to the International Statistical Classification of Diseases
and Related Health Problems, 10th revision [ICD-10],Diagnostic and Statistical Manual of Mental Disorders,
3rd edition, revised [DSM-III-R], and DSM-IV), which
consists of 10 questions [67]. The questionnaire also
included questions about the number of cigarettes smoked
per day (CPD) and other smoking-related traits (see
Additional file 5: Supporting Information). In the present
study, the FTND, TDS, and CPD were used as measures
of nicotine dependence (Additional file 12: Table S11).Genotyping
Whole-genome genotyping and quality control
A total of 300 DNA samples from the patients with smok-
ing behavior data who visited Iwata City Hospital were
used for genotyping. Whole-genome genotyping was per-
formed using the Infinium assay II (Illumina, San Diego,
CA, USA) with HumanCytoSNP-12 v2.0 (total markers:
301,232) BeadChips (see Additional file 5: Supporting
Information).
A total of 225,602 SNP markers survived the initial
filtration process as described in the Additional file 5: Sup-
porting Information, and a total of 225,591 SNP markers
were finally used for the GWAS after filtration using the
Hardy-Weinberg equilibrium test (Additional file 13:
Figure S1).Genotyping for specific candidate SNPs
The TaqMan allelic discrimination assay (Life Technolo-
gies, Carlsbad, CA, USA) was adopted for a total of 112
and 203 DNA samples from patients who underwent
major abdominal surgery and patients with METH de-
pendence/psychosis, respectively. Additional file 14: Table
S12 provides the genotype distribution of the candidate
SNPs. The details of genomic DNA extraction and the
TaqMan allelic discrimination assay are described in the
Additional file 5: Supporting Information and previous
reports [68].Array-based genotyping procedure for data extraction of a
specific SNP
To genotype the rs2653349 SNP for a total of 311 and
2,305 DNA samples from healthy subjects with schizo-
typal personality trait data and autopsy specimens, re-
spectively, array-based genotyping was conducted. The
genotype data for this SNP were extracted from the over-
all results. In the former case, genotyping was performed
using Affymetrix Genome-Wide Human SNP Array 6.0
(Affymetrix, Santa Clara, CA, USA) as previously de-
scribed [69]. In the latter case, all of the samples were ge-
notyped using Illumina Infinium HumanExome Beadchips
(Illumina, CA, USA, USA) with iScan. The details are
described in the Additional file 5: Supporting Information.
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Genome-wide association study
A two-stage GWAS was conducted for patients with
smoking behavior data to initially investigate the associ-
ation between genetic variations and the severity of nico-
tine dependence as an exploratory study to narrow down
candidate SNPs. Among the 300 subjects genotyped, ap-
proximately half lacked smoking behavior data that were
related to nicotine dependence. Therefore, a total of 148
subjects were used for our two-stage GWAS (68 and 80
subjects for the first- and second-stage analyses, respect-
ively). In our two-stage GWAS, 225,591 SNPs were
selected for the analyses.
The FTND, TDS, and CPD data were used as an index
of nicotine dependence for the GWAS. Prior to the ana-
lyses, the subjects were divided into two subgroups: low
dependence (FTND< 4, TDS < 3, CPD ≤ 20) and high
dependence (FTND ≥ 4, TDS ≥ 3, CPD > 20). The associ-
ation with SNPs was explored using Cochran-Armitage
trend tests. All of the statistical analyses were performed
using gPLINK v. 2.050, PLINK v. 1.07 (http://pngu.mgh.
harvard.edu/purcell/plink/; accessed April 19, 2014) [70]
and Haploview v. 4.1 [71].
The GWAS procedure is summarized in Additional file
13: Figure S1. In the first-stage analysis with 68 samples,
the SNPs that showed p < 0.05 were selected as candidate
SNPs for the second-stage analysis among the 225,591
SNPs. For these SNPs, the second-stage analysis was
conducted with 80 samples, and the SNPs that showed
p < 0.05 for the single analysis of this stage and combined
analysis of the first and second stages were considered po-
tent candidates. The SNPs for further replication analysis
were selected from these SNPs after linkage disequilib-
rium (LD)-based SNP pruning to remove redundant SNPs
due to strong LD with each other (see Additional file 5:
Supporting Information). In the confirmatory replication
study to corroborate the possible association between the
SNPs that were selected after the second stage and pheno-
typic trait, the q values of the false discovery rate were
calculated to correct for multiple testing, in addition to p
values based on previous reports [72, 73]. The SNPs that
showed q < 0.05 in the analysis were considered statisti-
cally significant. A log quantile-quantile (QQ) p-value plot
based on the results of the GWAS for the combined
samples was subsequently drawn to check the pattern of
the generated p-value distribution (Additional file 15:
Figure S2).
Association study for candidate SNP
For all of the genotype data used in the additional analyses
after the GWAS, the distributions were checked using the
χ2 test, and the absence of significant deviation from the
theoretical distribution expected from Hardy-Weinberg
equilibrium was confirmed (Additional file 14: Table S12).To explore the association between the rs2653349 SNP and
phenotypes, the Mann–Whitney U-test, the χ2 test, and
Fisher’s exact test were performed. The statistical methods
and software used in the analyses for the candidate SNP are
provided in the Additional file 5: Supporting Information.
The criterion for significance was set at p < 0.05.
Additional in silico analysis
The databases, power analysis, and imputation analysis,
which were based on previous reports [74–76], are de-
scribed in the Additional file 5: Supporting Information.
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